ReviewPsychopharmacology2013
Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.
Review in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Urinary organic acid levels and their associations with clinical characteristics in patients with schizophrenia.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Concomitant Hypertriglyceridemia-Induced Pancreatitis and Diabetic Ketoacidosis in the Setting of Olanzapine Use: A Case Report.Clinical case reports · 2026Article
- The Pathobiological Underpinnings of Psychosis: From the Stress-Related Hypothesis to a Multisystemic Approach.NeuroSci · 2025Review
- Atypical antipsychotic drugs cause abnormal glucose and lipid metabolism independent of weight gain.European archives of psychiatry and clinical neuroscience · 2025Article
- Article
- Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2023Article
- Vitamin D supplementation is effective for olanzapine-induced dyslipidemia.Frontiers in pharmacology · 2023Article
- Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders.Journal of personalized medicine · 2021Article
- Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics.Medical sciences (Basel, Switzerland) · 2020Review
- A Comprehensive Update on the Chylomicronemia Syndrome.Frontiers in endocrinology · 2020Review
- Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome.Frontiers in psychiatry · 2019Article
- Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study.Psychopharmacology · 2017Article
- Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.Translational psychiatry · 2016Article
- Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects.The mental health clinician · 2016Article
- Fatty acid transport protein-2 inhibitor Grassofermata/CB5 protects cells against lipid accumulation and toxicity.Biochemical and biophysical research communications · 2015Article
- Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.Drug safety · 2015Article
- Quetiapine-induced hypertriglyceridaemia causing acute pancreatitis.BMJ case reports · 2015Article
- Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics.Psychiatry investigation · 2015Article
- Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.Psychopharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
backgroundThe development of atypical antipsychotic (AAP) drugs has brought about dramatic improvement in the function of many patients with schizophrenia and related mental disorders. However, prescription of AAPs is frequently associated with the emergence of weight gain, hypertriglyceridemia, and other metabolic disturbances. Although the mechanisms involved in AAP-induced hypertriglyceridemia remain to be fully elucidated, several studies have proposed that this side effect may be associated with weight gain and obesity. Recently, special emphasis has been placed on the evidence indicating a direct effect of AAPs on triglyceride metabolism.
objectivesIn this review, we highlight recent findings discussing the potential mechanisms by which AAPs may contribute to hypertriglyceridemia. In addition, we summarize the adjunctive pharmacologic treatments for AAP-associated dyslipidemia.
conclusionsThere is evidence that AAPs may cause hypertriglyceridemia through several possible mechanisms: (1) a direct effect on triglyceride metabolism either by stimulation of hepatic triglyceride production and secretion or by inhibition of lipoprotein lipase-mediated triglyceride hydrolysis and (2) an indirect mechanism associated with obesity and insulin resistance. The practical applications of this manuscript provide new insights for the future investigation of AAPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.